Search research articles
Contact Us
Filters
Showing results (71-80 of 149) with videos related to
Page
of 15
Sort By:
British Journal of Haematology
|
November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study
Massimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica
|
January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study
Massimo Offidani, Laura Corvatta, Monica Marconi, et al.
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Cancer
|
June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Francesca Gay, Andreas Günther, Massimo Offidani, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Blood
|
April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
Cancer
|
December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella, Paola Omedé, Stefano Spada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
Michele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Oncotarget
|
June 6, 2015
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
Ingrid Cifola, Marta Lionetti, Eva Pinatel, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 149) with videos related to
Sort By:
Page
of 15
British Journal of Haematology
|
November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study
Massimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica
|
January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study
Massimo Offidani, Laura Corvatta, Monica Marconi, et al.
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Cancer
|
June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Francesca Gay, Andreas Günther, Massimo Offidani, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Blood
|
April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
Cancer
|
December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella, Paola Omedé, Stefano Spada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
Michele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Oncotarget
|
June 6, 2015
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
Ingrid Cifola, Marta Lionetti, Eva Pinatel, et al.
Page
of 15